GeneDx Holdings (WGS) Cash & Equivalents (2020 - 2026)

GeneDx Holdings (WGS) has reported Cash & Equivalents for 7 consecutive years, with $93.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 5.8% year-over-year to $93.9 million; the TTM figure through Mar 2026 stood at $93.9 million (down 5.8% YoY), while the FY2025 annual figure was $105.0 million, up 23.22% from the prior year.
• Cash & Equivalents slipped to $93.9 million in Q1 2026 per WGS's latest filing, from $105.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $315.0 million in Q1 2022 and bottomed at $56.1 million in Q2 2024.
• Historically, Cash & Equivalents has averaged $130.1 million across 5 years, with a median of $99.7 million in 2023.
• On a YoY basis, Cash & Equivalents climbed as much as 973.92% in 2022 and fell as far as 69.06% in 2022.
• GeneDx Holdings' Cash & Equivalents stood at $123.9 million in 2022, then declined by 19.57% to $99.7 million in 2023, then decreased by 14.52% to $85.2 million in 2024, then rose by 23.22% to $105.0 million in 2025, then retreated by 10.55% to $93.9 million in 2026.
• Business Quant data shows WGS's Cash & Equivalents at $93.9 million in Q1 2026, $105.0 million in Q4 2025, and $96.0 million in Q3 2025.